Na Zhao

Early dynamics of a neutrophil interferon program drive immunotherapy resistance and limit durable anti-tumor immunity

This study identifies an early neutrophil interferon program that predicts resistance to anti-PD1 therapy and limits durable anti-tumor immunity.

MERTK inhibition cooperates with immunomodulatory cyclophosphamide to induce CXCL9⁺ monocyte-macrophage programming and durable anti-tumor immunity in triple negative breast cancer

This paper shows that combining MERTK inhibition with cyclophosphamide enhances anti-tumor immunity in basal-like TNBC by reprogramming macrophages and promoting CD4 T cell responses.

Anti-CSF-1R therapy with combined immuno- chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched Triple Negative Breast Cancers

The paper shows that combining anti-CSF-1R therapy with chemotherapy and anti-PD-1 improves immune response in metastatic TNBC by reducing macrophages and increasing T/B cell infiltration.

Patient-Derived Xenograft-Guided Prediction of Chemotherapy Response in Triple-Negative Breast Cancer

This paper develops chemotherapy-specific predictors for triple-negative breast cancer using patient-derived xenografts and multi-omic data, achieving high AUROC scores for response prediction.

RPS19 and RPL5, the most commonly mutated genes in Diamond Blackfan anemia, impact DNA double-strand break repair

This study shows that RPS19 and RPL5 mutations in DBA impair DNA double-strand break repair, potentially explaining cancer risk in patients.

CBP/P300 BRD Inhibition Reduces Neutrophil Accumulation and Activates Antitumor Immunity in TNBC

CBP/P300 BRD inhibition reduces neutrophil accumulation and enhances antitumor immunity in neutrophil-enriched TNBC, improving responses to standard therapies.